Therapeutic goals include raising urinary citrate and increasing urinary pH

Urocit®-K at a dosage of 60 mEq/day will:

Raise urinary citrate by ~400 mg/day1

Increase urinary pH by ~0.7 units1

Provide a maximum-strength tablet for multiple conditions

Urocit-K dosage information1,2

Treatment with extended-release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least 2 liters per day). Urocit-K 15 mEq (1620 mg) should be taken with meals or within 30 minutes after meals or bedtime snacks.

Urocit-K treatment outcomes

Effect of Urocit-K in patients with calcium oxalate nephrolithiasis1

*Remission defined as “the percentage of patients remaining free of newly formed stones during treatment.” Group I: n=19 (10 renal tubular acidosis, 9 chronic diarrheal syndrome). Group II: n=37 (5 uric acid stones alone, 6 uric acid lithiasis and calcium stones, 3 type I absorptive hypercalciuria, 9 type II absorptive hypercalciuria and 14 hypocitraturia). Group III: n=15 (history of relapse on other therapy). Group IV: n=18 (9 type I absorptive hypercalciuria and calcium stones, 1 type II absorptive hypercalciuria and calcium stones, 2 hyperuricosuria calcium oxalate nephrolithiasis, 4 uric acid lithiasis accompanied by calcium stones and 2 hypocitraturia and hyperuricemia accompanied by calcium stones).

Manage a variety of kidney stone conditions

Urocit-K 15 mEq inhibits stone formation in more than 90% of
patients
3,4,5

Urocit-K may benefit your patients

Prescribe maximum-strength Urocit-K 15 mEq for patients who may:

  • Prefer taking fewer tablets per day which may help reduce pill burden

References: 1. Urocit-K [package insert]. San Antonio, TX: Mission Pharmacal Company. 2. Pak CYC, Fuller C, Sakhaee K, et al. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985;134(1):11-19. 3. Preminger GM, Sakhaee K, Skurla C, et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985;134(1):20-23. 4. Pak CYC, Peterson R, Sakhaee K, et al. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med. 1985;79(3):284-288. 5. Lipkin ME, Preminger GM. Demystifying the medical management of nephrolithiasis. Rev Urol. 2011;13(1):34-38.

Mission Pharmacal Company
San Antonio, TX 78230-1355
(210) 696-8400

This material is intended to provide basic information and is not medical advice. All medical advice, diagnosis, and treatment should be obtained from your physician. The product information provided in this site is intended for residents of the United States.

Copyright © 2021 Mission Pharmacal Company. All rights reserved.

This material is intended to provide basic information and is not medical advice. All medical advice, diagnosis, and treatment should be obtained from your physician. The product information provided in this site is intended for residents of the United States.

Copyright © 2020 Mission Pharmacal Company. All rights reserved.
Mission Pharmacal Company | P.O. Box 786099 | San Antonio, TX

Important Safety Information: